ES3058346T3 - Derivados que tienen un resto 2,3-dihidro-1H-indeno o 2,3-dihidrobenzofurano o una sal farmacéuticamente aceptable de mismo y composiciones farmacéuticas que comprenden los mismos - Google Patents

Derivados que tienen un resto 2,3-dihidro-1H-indeno o 2,3-dihidrobenzofurano o una sal farmacéuticamente aceptable de mismo y composiciones farmacéuticas que comprenden los mismos

Info

Publication number
ES3058346T3
ES3058346T3 ES24163536T ES24163536T ES3058346T3 ES 3058346 T3 ES3058346 T3 ES 3058346T3 ES 24163536 T ES24163536 T ES 24163536T ES 24163536 T ES24163536 T ES 24163536T ES 3058346 T3 ES3058346 T3 ES 3058346T3
Authority
ES
Spain
Prior art keywords
dihydro
inden
quinuclidin
carbamate
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES24163536T
Other languages
English (en)
Spanish (es)
Inventor
Dong-Hoon Kim
Jae-Eun Joo
Eui-Chul Lee
Tae-Dong Han
Seung-Yub Shin
Sool-Ki Kwon
Ji-Hye Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yuhan Corp
GC Cell Corp
Original Assignee
Yuhan Corp
Green Cross Lab Cell Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp, Green Cross Lab Cell Corp filed Critical Yuhan Corp
Application granted granted Critical
Publication of ES3058346T3 publication Critical patent/ES3058346T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES24163536T 2019-11-15 2020-11-12 Derivados que tienen un resto 2,3-dihidro-1H-indeno o 2,3-dihidrobenzofurano o una sal farmacéuticamente aceptable de mismo y composiciones farmacéuticas que comprenden los mismos Active ES3058346T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20190146679 2019-11-15

Publications (1)

Publication Number Publication Date
ES3058346T3 true ES3058346T3 (es) 2026-03-10

Family

ID=75911374

Family Applications (2)

Application Number Title Priority Date Filing Date
ES24163536T Active ES3058346T3 (es) 2019-11-15 2020-11-12 Derivados que tienen un resto 2,3-dihidro-1H-indeno o 2,3-dihidrobenzofurano o una sal farmacéuticamente aceptable de mismo y composiciones farmacéuticas que comprenden los mismos
ES20887669T Active ES2984255T3 (es) 2019-11-15 2020-11-12 Derivados que tienen un resto 2,3-dihidro-1H-indeno o 2,3-dihidrobenzofurano o una sal farmacéuticamente aceptable de mismo y composiciones farmacéuticas que comprenden los mismos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES20887669T Active ES2984255T3 (es) 2019-11-15 2020-11-12 Derivados que tienen un resto 2,3-dihidro-1H-indeno o 2,3-dihidrobenzofurano o una sal farmacéuticamente aceptable de mismo y composiciones farmacéuticas que comprenden los mismos

Country Status (13)

Country Link
US (2) US12522602B2 (pl)
EP (2) EP4389744B1 (pl)
JP (2) JP7671751B2 (pl)
KR (1) KR20210059632A (pl)
CN (2) CN114829361B (pl)
AU (1) AU2020384066B2 (pl)
BR (1) BR112022009409A2 (pl)
CA (1) CA3154313A1 (pl)
ES (2) ES3058346T3 (pl)
MX (1) MX2022005679A (pl)
PL (1) PL4041733T3 (pl)
RS (1) RS65662B1 (pl)
WO (1) WO2021096238A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020003242A (es) 2017-09-22 2020-09-18 Jubilant Epipad LLC Compuestos heterociclicos como inhibidores de pad.
AU2018352142B2 (en) 2017-10-18 2022-08-25 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
KR20200085836A (ko) 2017-11-06 2020-07-15 주빌런트 프로델 엘엘씨 Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체
BR112020010322A2 (pt) 2017-11-24 2020-11-17 Jubilant Episcribe Llc composto da fórmula i; composto da fórmula ia; composto da fórmula ib; processo de preparação de compostos da fórmula i; composição farmacêutica; método para o tratamento e/ou prevenção de várias doenças; uso dos compostos; método para o tratamento de câncer; e método para o tratamento e/ou prevenção de uma afecção mediada por prmt5 ou um distúrbio proliferativo ou câncer
SG11202008950PA (en) 2018-03-13 2020-10-29 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
IL306116A (en) * 2021-05-11 2023-11-01 Yuhan Corp New compounds with inhibitory activity against glucosylceramide synthase or an acceptable pharmaceutical salt thereof, processes for their preparation and pharmaceutical preparations containing them
KR20240035820A (ko) 2021-07-09 2024-03-18 플렉시움 인코포레이티드 Ikzf2를 조절하는 아릴 화합물 및 약학 조성물
CA3268132A1 (en) * 2022-10-24 2024-05-02 Yuhan Corporation NEW DIMETHYL-2,3-DIHYDRO-1H-INDENE DERIVATIVE SALT AND ITS PREPARATION PROCESSES
JP2025534728A (ja) * 2022-10-24 2025-10-17 ユーハン・コーポレイション ジメチル－２，３－ジヒドロ－１ｈ－インデン誘導体の改良された製造方法
WO2025032129A1 (en) 2023-08-08 2025-02-13 Syngenta Crop Protection Ag Novel aminoindane and aminotetraline compounds
KR20250117295A (ko) * 2024-01-26 2025-08-04 주식회사유한양행 고셔병의 예방 또는 치료용 약제학적 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
US8003617B2 (en) 2004-11-10 2011-08-23 Genzyme Corporation Methods of treating diabetes mellitus
US8030081B2 (en) 2007-02-28 2011-10-04 Denka Seiken Co., Ltd. Reagent for quantitative determination of small, dense LDLs
EP2594562B1 (en) 2007-05-31 2016-07-20 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
WO2009117150A2 (en) 2008-03-20 2009-09-24 Genzyme Corporation Method of treating lupus with ceramide derivatives
CA2731685A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
WO2010091164A1 (en) 2009-02-06 2010-08-12 Exelixis, Inc. Inhibitors of glucosylceramide synthase
WO2010091104A1 (en) 2009-02-06 2010-08-12 Exelixis, Inc. Glucosylceramide synthase inhibitors
AU2012231275A1 (en) 2011-03-18 2013-10-17 Genzyme Corporation Glucosylceramide synthase inhibitors
WO2013059119A1 (en) * 2011-10-17 2013-04-25 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
CN105745206B (zh) * 2013-09-20 2019-08-13 生物马林药物股份有限公司 用于治疗疾病的葡萄糖神经酰胺合成酶抑制剂
TW201642855A (zh) * 2015-03-10 2016-12-16 健臻公司 用於治療蛋白質病變之方法
US10604514B2 (en) 2017-10-19 2020-03-31 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof
US20200308168A1 (en) * 2017-12-04 2020-10-01 Friedrich-Alexander-Universität Erlangen-Nürnberg Fluorophenyl substituted muscarinic receptor ligands with selectivity for m3 over m2

Also Published As

Publication number Publication date
EP4041733C0 (en) 2024-05-08
EP4041733A4 (en) 2023-08-30
AU2020384066B2 (en) 2025-10-30
JP2025111591A (ja) 2025-07-30
BR112022009409A2 (pt) 2022-08-09
ES2984255T3 (es) 2024-10-29
EP4389744C0 (en) 2025-12-03
CN118955495A (zh) 2024-11-15
JP7671751B2 (ja) 2025-05-02
RS65662B1 (sr) 2024-07-31
CA3154313A1 (en) 2021-05-20
PL4041733T3 (pl) 2024-09-23
MX2022005679A (es) 2022-06-27
AU2020384066A1 (en) 2022-04-21
EP4389744A1 (en) 2024-06-26
EP4041733A1 (en) 2022-08-17
JP2023503830A (ja) 2023-02-01
WO2021096238A1 (en) 2021-05-20
CN114829361B (zh) 2024-07-16
US12522602B2 (en) 2026-01-13
US20230002379A1 (en) 2023-01-05
EP4389744B1 (en) 2025-12-03
KR20210059632A (ko) 2021-05-25
CN114829361A (zh) 2022-07-29
US20260098038A1 (en) 2026-04-09
EP4041733B1 (en) 2024-05-08

Similar Documents

Publication Publication Date Title
ES3058346T3 (es) Derivados que tienen un resto 2,3-dihidro-1H-indeno o 2,3-dihidrobenzofurano o una sal farmacéuticamente aceptable de mismo y composiciones farmacéuticas que comprenden los mismos
ES2982711T3 (es) Derivados que tienen un resto 1,2,3,4-tetrahidronaftaleno o una sal farmacéuticamente aceptable de los mismos y composiciones farmacéuticas que comprenden los mismos
KR20190140005A (ko) 디히드로오로테이트 옥시게나제 억제제로서의 삼치환 벤조트리아졸 유도체의 사용 방법
US20240262819A1 (en) Novel compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically acceptable salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the same
RU2826099C1 (ru) Новые производные, имеющие фрагмент 2,3-дигидро-1h-индена или 2,3-дигидробензофурана, или их фармацевтически приемлемая соль и содержащие их фармацевтические композиции
HK40068976B (zh) 具有2，3-二氢-1h-茚或2，3-二氢苯并呋喃部分的衍生物或其药学上可接受盐及含其的药物组合物
HK40068976A (en) Derivatives having 2,3-dihydro-1h-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same
JP7144863B2 (ja) イソキノリン化合物、その調製の方法、およびベータガラクトシダーゼの活性の変質に伴う状態におけるその治療的使用
JP6422018B2 (ja) 糖脂質代謝異常症処置剤
HK40014193A (en) Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase
HK40014193B (en) Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase
US20180305341A1 (en) Imidazolinone derivatives as trpm8 antagonists